Cetrorelix
Also referenced as: Cetrotide
A GnRH antagonist used in controlled ovarian stimulation.
- Evidence grade
- AStrong Clinical Evidence
Strong Clinical Evidence
- Regulatory status
- FDA Approved for Specific Indication
FDA-approved to inhibit premature LH surges during controlled ovarian stimulation.
- Human data
- Yes
Registered clinical trials exist
- Last reviewed
- October 27, 2026
Overview
A GnRH antagonist used in controlled ovarian stimulation.
FDA-approved to inhibit premature LH surges during controlled ovarian stimulation.
A protocol-specific LH effect is not proof of better outcomes in all fertility settings.
Why It's Being Studied
- Controlled ovarian stimulation
- LH surge prevention
Mechanism of Action
Rapid pituitary GnRH-receptor blockade suppresses LH and FSH release, preventing a premature LH surge.
Rapid pituitary GnRH-receptor blockade suppresses LH and FSH release, preventing a premature LH surge. A protocol-specific LH effect is not proof of better outcomes in all fertility settings.
From molecular target to clinical evidence
Tap each stage to see what happens.
Background: Clinical Peptide Medicines
Clinical peptide medicines include endocrine treatments, antimicrobial drugs, receptor blockers and targeted diagnostic or cancer agents. They do not share one mechanism or one set of indications.
An approval belongs to a specific medicine and indication. A diagnostic tracer, an antibiotic and a hormone are not interchangeable wellness products; read each profile's own mechanism and prescribing source.
Research Areas & Routes Studied
- Controlled ovarian stimulation
- LH surge prevention
- Subcutaneous approved medicine
Evidence Summary
Clinical evidence supports its assisted-reproduction protocol role, not generalized fertility enhancement.
Higher tiers carry more weight. Filled tiers have evidence for Cetrorelix; tap to read it.
- Clinical evidence supports its assisted-reproduction protocol role, not generalized fertility enhancement.
1 cited sources.
- Prescribing label1
Human clinical evidence
- Clinical evidence supports its assisted-reproduction protocol role, not generalized fertility enhancement.
Reported Adverse Events in Research
- Hypersensitivity or anaphylaxis and injection reactions are concerns; ovarian hyperstimulation can occur in the associated treatment regimen.
Limitations of Current Evidence
- A protocol-specific LH effect is not proof of better outcomes in all fertility settings.
- Findings apply to the product, route and population studied; they do not establish benefits or safety for unrelated wellness uses or research-vial products.
How to Read This Research
- Is this a single molecule or a family of medicines?
- Is the use diagnostic, therapeutic or investigational?
- Does the quoted outcome match the exact product, formulation and population?
- Use the compound-specific mechanism above; this diagram describes drug development, not a shared biological pathway.
- Historical approval, present availability and off-label use are distinct questions.
- For radiopharmaceuticals and hospital medicines, specialist handling is part of the treatment context.
- Indication
- The condition and population for which a medicine is approved.
- Antagonist
- A compound that blocks activity at a receptor.
- Radiopharmaceutical
- A medicine containing a radioactive isotope for imaging or treatment.
Compare With Other Compounds
| Cetrorelix | Trofinetide | |
|---|---|---|
| Evidence grade | A — Strong Clinical Evidence | B — Moderate Human Evidence |
| Regulatory status | FDA Approved for Specific Indication | FDA Approved for Specific Indication |
| Human data | Yes | Yes |
| Clinical trials | Registered trials exist | Registered trials exist |
| Research routes | Subcutaneous approved medicine | Oral approved medicine |
| Cited sources | 1 | 2 |
Frequently Asked Questions
Research References
- Prescribing label
Cetrorelix — prescribing label